{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:21:19Z","timestamp":1792092079498,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017607","name":"Shenzhen Basic Research Program","doi-asserted-by":"publisher","award":["JCYJ20220818100412028"],"award-info":[{"award-number":["JCYJ20220818100412028"]}],"id":[{"id":"10.13039\/501100017607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA0909300"],"award-info":[{"award-number":["2021YFA0909300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jbc.2025.110449","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:55:38Z","timestamp":1751457338000},"page":"110449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Targeted degradation of \u03b1-synuclein by arginine-based PROTACs"],"prefix":"10.1016","volume":"301","author":[{"given":"Linjing","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2025.110449_bib1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.jbc.2025.110449_bib2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00018-022-04240-2","article-title":"Initiation and progression of alpha-synuclein pathology in Parkinson's disease","volume":"79","author":"Tofaris","year":"2022","journal-title":"Cell Mol. Life. Sci."},{"key":"10.1016\/j.jbc.2025.110449_bib3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jbc.2025.110449_bib4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.jbc.2025.110449_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102441","article-title":"TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: from pathomechanisms to therapeutic strategies","volume":"100","author":"Ho","year":"2024","journal-title":"Ageing. Res. Rev."},{"key":"10.1016\/j.jbc.2025.110449_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jbc.2025.110449_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer's disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.jbc.2025.110449_bib8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jbc.2025.110449_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2025.110449_bib10","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110449_bib11","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1073\/pnas.132197599","article-title":"Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice","volume":"99","author":"Lee","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110449_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jbc.2025.110449_bib13","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jbc.2025.110449_bib14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1073\/pnas.97.2.571","article-title":"Acceleration of oligomerization, not fibrillization, is a shared property of both \u03b1-synuclein mutations linked to early-onset Parkinson\u2019s disease: implications for pathogenesis and therapy","volume":"97","author":"Kelly","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110449_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.jbc.2025.110449_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jbc.2025.110449_bib17","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jbc.2025.110449_bib18","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acsmedchemlett.0c00192","article-title":"PROTAC compounds targeting alpha-synuclein protein for treating neurogenerative disorders: Alzheimer's and Parkinson's diseases","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS. Med. Chem. Lett."},{"key":"10.1016\/j.jbc.2025.110449_bib19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2014.10.006","article-title":"Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus","volume":"453","author":"Montrose","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbc.2025.110449_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway","volume":"146","author":"Lu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jbc.2025.110449_bib21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/acsmedchemlett.9b00385","article-title":"PROTAC degradation of IRAK4 for the treatment of neurodegenerative and cardiovascular diseases","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS. Med. Chem. Lett."},{"key":"10.1016\/j.jbc.2025.110449_bib22","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS. Cent. Sci."},{"key":"10.1016\/j.jbc.2025.110449_bib23","article-title":"Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies","volume":"1867","author":"Jangampalli Adi","year":"2021","journal-title":"Biochim. Biophys. Acta. Mol. Basis. Dis."},{"key":"10.1016\/j.jbc.2025.110449_bib24","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.chembiol.2020.03.010","article-title":"Specific knockdown of alpha-synuclein by peptide-directed proteasome degradation rescued its associated neurotoxicity","volume":"27","author":"Qu","year":"2020","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.jbc.2025.110449_bib25","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.3390\/molecules28114458","article-title":"Design, synthesis and biological evaluation of alpha-synuclein proteolysis-targeting chimeras","volume":"28","author":"Wen","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jbc.2025.110449_bib26","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1021\/acs.jmedchem.3c01719","article-title":"Discovery of effective dual PROTAC degraders for neurodegenerative disease-associated aggregates","volume":"67","author":"Zhu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jbc.2025.110449_bib27","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3390\/pharmaceutics15051467","article-title":"Synthesis and preliminary characterization of putative anle138b-centered PROTACs against alpha-synuclein aggregation","volume":"15","author":"Pedrini","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jbc.2025.110449_bib28","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1021\/acs.jmedchem.3c00274","article-title":"Discovery of small-molecule degraders for alpha-synuclein aggregates","volume":"66","author":"Tong","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jbc.2025.110449_bib29","doi-asserted-by":"crossref","first-page":"15172","DOI":"10.1074\/jbc.AC119.010790","article-title":"A modular PROTAC design for target destruction using a degradation signal based on a single amino acid","volume":"294","author":"Shanmugasundaram","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110449_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104994","article-title":"Single amino acid-based PROTACs trigger degradation of the oncogenic kinase BCR-ABL in chronic myeloid leukemia (CML)","volume":"299","author":"Zhang","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110449_bib31","doi-asserted-by":"crossref","first-page":"13666","DOI":"10.1021\/acs.jmedchem.4c00208","article-title":"Distinct amino acid-based PROTACs target oncogenic kinases for degradation in non-small cell lung cancer (NSCLC)","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jbc.2025.110449_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-biochem-051710-093308","article-title":"The N-end rule pathway","volume":"81","author":"Tasaki","year":"2012","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jbc.2025.110449_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.3018930","article-title":"In vivo half-life of a protein is a function of its amino-terminal residue","volume":"234","author":"Bachmair","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.jbc.2025.110449_bib34","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"Alpha-synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jbc.2025.110449_bib35","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2174\/1381612043384772","article-title":"Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain","volume":"10","author":"Mathis","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jbc.2025.110449_bib36","doi-asserted-by":"crossref","first-page":"8892","DOI":"10.1039\/D1SC01263K","article-title":"Mapping the binding site topology of amyloid protein aggregates using multivalent ligands","volume":"12","author":"Sanna","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jbc.2025.110449_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-023-00921-7","article-title":"Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera","volume":"30","author":"Tseng","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jbc.2025.110449_bib38","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Exploration. Targeted. Anti. Tumor. Ther."},{"key":"10.1016\/j.jbc.2025.110449_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bbrc.2009.07.008","article-title":"Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease","volume":"387","author":"Kumar","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbc.2025.110449_bib40","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41598-022-10789-6","article-title":"Mechanisms of enhanced aggregation and fibril formation of Parkinson's disease-related variants of alpha-synuclein","volume":"12","author":"Ohgita","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2025.110449_bib41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2174\/1389203717666160314151706","article-title":"Alteration of structure and aggregation of alpha-synuclein by familial Parkinson's disease associated mutations","volume":"18","author":"Sahay","year":"2017","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.jbc.2025.110449_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/jnc.14704","article-title":"How is alpha-synuclein cleared from the cell?","volume":"150","author":"Stefanis","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jbc.2025.110449_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000027","article-title":"C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging","volume":"4","author":"van Ham","year":"2008","journal-title":"PLoS. Genet."},{"key":"10.1016\/j.jbc.2025.110449_bib44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cell.2010.07.020","article-title":"Identification of MOAG-4\/SERF as a regulator of age-related proteotoxicity","volume":"142","author":"van Ham","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2025.110449_bib45","doi-asserted-by":"crossref","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","article-title":"A natural product inhibits the initiation of alpha-synuclein aggregation and suppresses its toxicity","volume":"114","author":"Perni","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110449_bib46","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1007\/s12035-018-0881-7","article-title":"The small GTPase RAC1\/CED-10 is essential in maintaining dopaminergic neuron function and survival against alpha-synuclein-induced toxicity","volume":"55","author":"Kim","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jbc.2025.110449_bib47","doi-asserted-by":"crossref","first-page":"10481","DOI":"10.1073\/pnas.1804198115","article-title":"Small molecule inhibits alpha-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons","volume":"115","author":"Pujols","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110449_bib48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41598-021-04131-9","article-title":"Two-step screening method to identify alpha-synuclein aggregation inhibitors for Parkinson's disease","volume":"12","author":"Hideshima","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2025.110449_bib49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1471-4159.2003.01809.x","article-title":"Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein","volume":"86","author":"Lakso","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jbc.2025.110449_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165876","article-title":"TDP-1\/TDP-43 potentiates human alpha-Synuclein (HASN) neurodegeneration in Caenorhabditis elegans","volume":"1866","author":"Shen","year":"2020","journal-title":"Biochim. Biophys. Acta. Mol. Basis. Dis."},{"key":"10.1016\/j.jbc.2025.110449_bib51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.jbc.2025.110449_bib52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2016.11.010","article-title":"Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders","volume":"172","author":"Hasegawa","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jbc.2025.110449_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11910-014-0495-z","article-title":"Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies","volume":"14","author":"Goedert","year":"2014","journal-title":"Curr. Neurol. Neurosci."},{"key":"10.1016\/j.jbc.2025.110449_bib54","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.neurol.2015.09.010","article-title":"[Spreading of protein misfolding: a new paradigm in neurology]","volume":"171","author":"Hauw","year":"2015","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.jbc.2025.110449_bib55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.conb.2019.11.018","article-title":"Prion-like properties of assembled TDP-43","volume":"61","author":"Nonaka","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.jbc.2025.110449_bib56","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3390\/cancers14061417","article-title":"Spreading of alpha synuclein from glioblastoma cells towards astrocytes correlates with stem-like properties","volume":"14","author":"Ryskalin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbc.2025.110449_bib57","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/brain\/awaa096","article-title":"Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates","volume":"143","author":"Arotcarena","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.jbc.2025.110449_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-015-1517-x","article-title":"Propagation of Abeta, tau and alpha-synuclein pathology between experimental models and human reality: prions, propagons and propaganda","volume":"131","author":"Uchihara","year":"2016","journal-title":"Acta. Neuropathol."},{"key":"10.1016\/j.jbc.2025.110449_bib59","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s12276-020-00513-7","article-title":"The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies","volume":"52","author":"Jo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jbc.2025.110449_bib60","series-title":"Maintenance of C. elegans. WormBook","first-page":"1","author":"Stiernagle","year":"2006"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825022999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825022999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T23:26:42Z","timestamp":1756423602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925825022999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0021925825022999"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110449","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted degradation of \u03b1-synuclein by arginine-based PROTACs","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology\u00e9","name":"copyright","label":"Copyright"}],"article-number":"110449"}}